

Educational Sessions

Wednesday, 10 October 2018

08.00 – 09.30	Educational Session 1: Pregnancy management in MS	Hall D
	Level: Basic	
	Chairs: <i>K. Hellwig (Bochum, DE)</i> <i>A. Langer Gould (Pasadena, US)</i>	
08.00	Symptomatic MS treatment and pregnancy / lactation management <i>M. Magyari (Copenhagen, DK)</i>	
08.30	The natural history of MS during pregnancy and the postpartum period in contemporary MS cohorts <i>A. Langer Gould (Pasadena, US)</i>	
09.00	Multiple sclerosis and pregnancy management in 2018: MS medications and lactation <i>K. Hellwig (Bochum, DE)</i>	

08.00 – 09.30	Educational Session 2: Practical treatment recommendations based on new guidelines in MS	Hall E
	Level: Basic	
	Chairs: <i>X. Montalban (Barcelona, ES)</i> <i>D. Pelletier (Los Angeles, US)</i>	
	Detailed programme to be announced	

08.00 – 09.30	Educational Session 3: Neurofilament light chains in MS: where do we stand, the long road to clinical application	Hall F
	Level: Intermediate	
	Chairs: <i>C. Teunissen (Amsterdam, NL)</i> <i>J. Kuhle (Basel, CH)</i>	
08.00	The evidence <i>J. Kuhle (Basel, CH)</i>	
08.30	The long road to clinical application <i>C. Teunissen (Amsterdam, NL)</i>	
09.00	Clinical application today and tomorrow <i>F. Piehl (Stockholm, SE)</i>	

08.00 – 09.30	Educational Session 4: Immunology of MS <i>Level: Advanced</i> Chairs: <i>E. Meinl (Martinsried, DE)</i> <i>V.W.W. Yong (Calgary, CA)</i>	Hall G
08.00	B and T cells in MS <i>E. Meinl (Martinsried, DE)</i>	
08.30	Myeloid cells in MS <i>V.W.W. Yong (Calgary, CA)</i>	
09.00	Systems immunology to model, predict, and monitor MS <i>C. Farina (Milan, IT)</i>	
<hr/>		
08.00 – 09.30	Educational Session 5: Impact and management of comorbidities in MS <i>Level: Intermediate</i> Chairs: <i>R.A. Marrie (Winnipeg, CA)</i> <i>H. Tremlett (Vancouver, CA)</i>	Hall H
08.00	Impact of comorbidity in MS <i>R.A. Marrie (Winnipeg, CA)</i>	
08.30	Bidirectional relationships between comorbidity and disease-modifying therapy <i>H. Tremlett (Vancouver, CA)</i>	
09.00	Management of psychiatric comorbidity in MS <i>A. Feinstein (Toronto, CA)</i>	
<hr/>		
09.45 – 10.30	Case-based Educational Session 6: How to manage non-response to highly active (second line) drugs? Chairs: <i>A.J. Coles (Cambridge, UK)</i> <i>J. Sastre-Garriga (Barcelona, ES)</i>	Hall F
09.45	Case 1 <i>A.J. Coles (Cambridge, UK)</i>	
10.07	Case 2 <i>J. Sastre-Garriga (Barcelona, ES)</i>	

09.45 – 10.30	Case-based Educational Session 7: Progressive MS: who should be treated and how to monitor treatment response?	Hall G
	Chairs: <i>B.A.C. Cree (San Francisco, US)</i> <i>R. Kapoor (London, UK)</i>	
09.45	Case 1 <i>B.A.C. Cree (San Francisco, US)</i>	
10.07	Case 2 <i>R. Kapoor (London, UK)</i>	
<hr/>		
09.45 – 10.30	Case-based Educational Session 8: Should all MS patients be treated?	Hall H
	Chairs: <i>A. Chan (Bern, CH)</i> <i>M. Stangel (Hannover, DE)</i>	
09.45	Pro <i>M. Stangel (Hannover, DE)</i>	
10.07	Con <i>A. Chan (Bern, CH)</i>	
<hr/>		
13.30 – 15.00	Educational Session 9: Clinical trials in MS: the need for novelty	Hall F
	Level: Advanced	
	Chairs: <i>M.P. Sormani (Genoa, IT)</i> <i>J. Chataway (London, UK)</i>	
13.30	Endpoints in MS clinical trials: going beyond EDSS <i>F. Pellegrini (Zug, CH)</i>	
14.00	More flexibility for future MS trials: adaptive designs <i>J. Chataway (London, UK)</i>	
14.30	Prognosis, response to therapy and treatment effect: easy to say, hard to measure <i>M.P. Sormani (Genoa, IT)</i>	
<hr/>		

-
- 13.30 – 15.00 **Educational Session 10: Innovation in MRI in relation to cognitive and neuropsychiatric phenomena in MS (IMSCOGS)** Hall G
- Level: Advanced**
- Chairs:
C. Enzinger (Graz, AT)
- 13.30 **Neuropathological injury in MS and relationship to structural MRI metrics**
J. Geurts (Amsterdam, NL)
- 14.00 **Functional MRI studies in MS: update on brain plasticity and repair**
C. Enzinger (Graz, AT)
- 14.30 **Functional relevance of MRI in early MS, correlation with cognitive performance and related outcomes**
B. Brochet (Bordeaux, FR)
-
- 13.30 – 15.00 **Educational Session 11: Molecular mechanisms of tissue injury in cortical MS lesions** Hall H
- Level: Advanced**
- Chairs:
J. Van Horssen (Amsterdam, NL)
D.J. Mahad (Edinburgh, UK)
- 13.30 **Unraveling the cause of neuronal mitochondrial dysfunction in MS**
J. Van Horssen (Amsterdam, NL)
- 14.00 **Uncovering the pathogenesis of synapse loss in cortical MS and its models**
M. Kerschensteiner (Munich, DE)
- 14.30 **Understanding the early clinical and pathological consequences of mitochondrial dysfunction in progressive MS**
D.J. Mahad (Edinburgh, UK)
-
- 15.30 – 17.00 **Educational Session 12: MS mimicks: other neuro-inflammatory disorders** Hall F
- Level: Basic**
- Chairs:
D.M. Wingerchuk (Scottsdale, US)
A. Siva (Istanbul, TR)
M. Keegan (Rochester, US)
- 15.30 **NMOSD and related autoantibody CNS Disorders**
A. Siva (Istanbul, TR)
- 16.00 **Atypical inflammatory syndromes of the CNS**
M. Keegan (Rochester, US)
- 16.30 **Primary and secondary inflammatory vasculopathies and other inflammatory disorders of the CNS mimicking MS**
C. Rice (Bristol, UK)
-

15.30 – 17.00	Educational Session 13: Genetics and biomarkers in MS	Hall G
	Level: Advanced	
	Chairs: <i>B. Hemmer (Munich, DE)</i> <i>M. Comabella (Barcelona, ES)</i>	
15.30	General considerations in biomarker research and application <i>B. Hemmer (Munich, DE)</i>	
16.00	Serum and CSF biomarkers in MS <i>M. Comabella (Barcelona, ES)</i>	
16.30	Basics of MS genetics <i>S.E. Baranzini (San Francisco, US)</i>	
<hr/>		
15.30 – 17.00	Educational Session 14: Myelin repair in MS	Hall H
	Level: Advanced	
	Chairs: <i>C. Lubetzki (Paris, FR)</i>	
15.30	What have we learnt on remyelination in MS? an historical perspective <i>C. Lubetzki (Paris, FR)</i>	
16.00	Promoting exogenous remyelination: from basic sciences to translation <i>S. Goldman (Copenhagen, DK)</i>	
16.30	Promoting endogenous remyelination: from basic sciences to trans <i>A. Green (San Francisco, US)</i>	

Thursday, 11 October 2018

08.00 – 09.30 **Educational Session 15: Disease modifying treatments in MS** Hall D
Level: Basic
Chairs:
H.-P. Hartung (Duesseldorf, DE)

Detailed programme to be announced

08.00 – 09.30 **Educational Session 16: Symptomatic treatment of MS:
how to manage pain/bladder/bowel/sexual dysfunction? (RIMS)** Hall E
Level: Basic
Chairs:
P.L. Eelen (Melsbroek, BE)
R. Moss Morris (London, UK)

08.00 **Management of bladder and bowel problems**
P.L. Eelen (Melsbroek, BE)

08.30 **Treatment of sexual dysfunction**
C.A. Young (Liverpool, UK)

09.00 **Pain management**
R. Moss Morris (London, UK)

10.00 – 11.30 **Educational Session 17: MS pathology for clinical neurologists** Hall D
Level: Basic
Chairs:
W. Brück (Göttingen, DE)
C. Stadelmann (Göttingen, DE)

10.00 **The white matter lesion in MS**
W. Brück (Göttingen, DE)

10.30 **The grey matter lesion in MS**
C. Stadelmann (Göttingen, DE)

11.00 **Inflammatory demyelination spectrum**
R. Höftberger (Vienna, AT)

10.00 – 11.30	Educational Session 18: Experimental neuroimmunology	Hall E
	Level: Advanced	
	Chairs: <i>A. Flügel (Göttingen, DE)</i> <i>T. Kuhlmann (Münster, DE)</i>	
10.00	Immunopathogenesis in CNS autoimmunity: lessons from animal models <i>A. Flügel (Göttingen, DE)</i>	
10.10	Experimental MS models and their relation to the human disease <i>T. Kuhlmann (Münster, DE)</i>	
10.20	Blood-brain barrier autoimmune function and dysfunction in CNS autoimmunity <i>B. Engelhardt (Bern, CH)</i>	
<hr/>		
11.45 – 12.45	Case-based Educational Session 19: Pediatric MS	Hall E
	Chairs: <i>T. Chitnis (Boston, US)</i> <i>J. Gärtner (Göttingen, DE)</i>	
11.45	What's in a name? Pediatric MS or another diagnosis? <i>T. Chitnis (Boston, US)</i>	
12.15	Treatment of highly active pediatric MS and potential treatment failures <i>J. Gärtner (Göttingen, DE)</i>	
<hr/>		
14.15 – 15.45	Educational Session 20: MRI and the diagnosis of multiple sclerosis (MAGNIMS)	Hall D
	Level: Basic	
	Chairs: <i>F. Barkhof (London, UK)</i> <i>M. Filippi (Milan, IT)</i>	
14.15	MRI and the diagnosis of MS: from MAGNIMS 2016 to the 2017 revision of the McDonald criteria <i>M. Filippi (Milan, IT)</i>	
14.45	Application of MRI diagnostic criteria in clinical practice <i>M. Tintoré (Barcelona, ES)</i>	
15.15	MRI and multiple sclerosis misdiagnosis and differential diagnosis <i>F. Barkhof (London, UK)</i>	

14.15 – 15.45	Educational Session 21: Symptomatic treatment of MS: how to manage fatigue and gait dysfunction? (RIMS) <i>Level: Basic</i> Chairs: <i>J. Kesselring (Valens, CH)</i> <i>V. de Groot (Amsterdam, NL)</i>	Hall E
14.15	Overview <i>J. Kesselring (Valens, CH)</i>	
14.45	Exercise therapy of gait dysfunction <i>P. Feys (Hasselt, BE)</i>	
15.15	Pharmacological and non-pharmacological treatment of fatigue <i>V. de Groot (Amsterdam, NL)</i>	
<hr/>		
16.15 – 17.15	Case-based Educational Session 22: MOG-Ab phenotype Chairs: <i>M. Weber (Göttingen, DE)</i> <i>T. Derfuss (Basel, CH)</i>	Hall E
16.15	Case 1 <i>M. Weber (Göttingen, DE)</i>	
16.45	Case 2 <i>T. Derfuss (Basel, CH)</i>	

Friday, 12 October 2018

08.30 – 10.00	Educational Session 23: NMO-spectrum disorders: current concepts and clinical management <i>Level: Intermediate</i> Chairs: <i>F. Paul (Berlin, DE)</i> <i>J. Palace (Oxford, UK)</i>	Hall D
08.30	NMOSD and AQP4-Ab positive disease classification and update on epidemiology and phenotypic features <i>F. Paul (Berlin, DE)</i>	
09.00	MOG antibody disease update and differentiation from MS and AQP4-Ab positive disease <i>K. Fujihara (Sendai, JP)</i>	
09.30	Treatment of NMOSD using case studies <i>J. Palace (Oxford, UK)</i>	

08.30 – 10.00	Educational Session 24: The use of stem cells in MS: where are we and where are we going? <i>Level: Intermediate</i> Chairs: <i>D. Karussis (Jerusalem, IS)</i> <i>A. Uccelli (Genoa, IT)</i>	Hall E
08.30	Overview of the rationale and the options of stem cells therapies in MS and review of the existing clinical experience <i>D. Karussis (Jerusalem, IS)</i>	
09.00	Mesenchymal stem cells in MS: possible mechanisms of action and future directions <i>A. Uccelli (Genoa, IT)</i>	
09.30	The rationale and the existing clinical data using Hematopoietic stem cells in MS <i>P.A. Muraro (London, UK)</i>	

10.30 – 12.00	Educational Session 25: MS mimicks: genetic disorders <i>Level: Basic</i> Chairs: <i>O. Boespflug-Tanguy (Paris, FR)</i>	Hall D
---------------	--	--------

Detailed programme to be announced

10.30 – 12.00	Educational Session 26: From structural and functional connectivity to clinical impairment in multiple sclerosis (MAGNIMS)	Hall E
	Level: Advanced	
	Chairs:	
	<i>M.A. Rocca (Milan, IT)</i>	
	<i>D. Chard (London, UK)</i>	
10.30	Structural connectivity	
	<i>C. Tur (London, UK)</i>	
11.00	Functional connectivity	
	<i>M.A. Rocca (Milan, IT)</i>	
11.30	Clinical significance	
	<i>D. Chard (London, UK)</i>	